Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 335

1.

Efficacy and safety of peginterferon alpha-2a (40KD) in HBeAg-positive chronic hepatitis B patients.

Caruntu FA, Streinu-Cercel A, Gheorghe LS, Grigorescu M, Sporea I, Stanciu C, Andronescu D, Voinea F, Diculescu M, Oproiu A, Voiosu R.

J Gastrointestin Liver Dis. 2009 Dec;18(4):425-31.

2.

Efficacy of thymosin α-1 plus peginterferon α-2a combination therapy compared with peginterferon α-2a monotherapy in HBeAg-positive chronic hepatitis B: a prospective, multicenter, randomized, open-label study.

Kim BH, Lee YJ, Kim W, Yoon JH, Jung EU, Park SJ, Kim YJ, Lee HS.

Scand J Gastroenterol. 2012 Sep;47(8-9):1048-55. doi: 10.3109/00365521.2012.694902. Epub 2012 Jun 25.

PMID:
22726105
3.

Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.

Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, Gane E, Fried MW, Chow WC, Paik SW, Chang WY, Berg T, Flisiak R, McCloud P, Pluck N; Peginterferon Alfa-2a HBeAg-Positive Chronic Hepatitis B Study Group.

N Engl J Med. 2005 Jun 30;352(26):2682-95.

4.

Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.

Marcellin P, Lau GK, Bonino F, Farci P, Hadziyannis S, Jin R, Lu ZM, Piratvisuth T, Germanidis G, Yurdaydin C, Diago M, Gurel S, Lai MY, Button P, Pluck N; Peginterferon Alfa-2a HBeAg-Negative Chronic Hepatitis B Study Group.

N Engl J Med. 2004 Sep 16;351(12):1206-17.

5.

Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B.

Lampertico P, Viganò M, Di Costanzo GG, Sagnelli E, Fasano M, Di Marco V, Boninsegna S, Farci P, Fargion S, Giuberti T, Iannacone C, Regep L, Massetto B, Facchetti F, Colombo M; PegBeLiver Study Group.

Gut. 2013 Feb;62(2):290-8. doi: 10.1136/gutjnl-2011-301430. Epub 2012 Aug 2.

PMID:
22859496
6.

Clinical Analysis of Polyethylene Glycol Interferon-α Treatment in 155 Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB) Patients.

Luo X, Yu JX, Xie L, Ma WJ, Wang LH.

Ann Hepatol. 2017 November-December,;16(6):888-892. doi: 10.5604/01.3001.0010.5279.

7.

Extended treatment with peginterferon α-2a in combination with lamivudine or adefovir for 96 weeks yields high rates of HBeAg and HBsAg seroconversion.

Cao ZH, Ma LN, Zhang HW, Liu YL, Chen XY.

J Dig Dis. 2013 Aug;14(8):446-50. doi: 10.1111/1751-2980.12065.

PMID:
23615131
8.

Peginterferon-α2a combined with response-guided short-term lamivudine improves response rate in hepatitis B e antigen-positive hepatitis B patients: a pilot study.

Huang Z, Deng H, Zhao Q, Zheng Y, Peng L, Lin C, Zhao Z, Gao Z.

Eur J Gastroenterol Hepatol. 2013 Oct;25(10):1165-9. doi: 10.1097/MEG.0b013e3283612e95.

PMID:
23571612
9.

Effect of host and viral factors on hepatitis B e antigen-positive chronic hepatitis B patients receiving pegylated interferon-α-2a therapy.

Tseng TC, Yu ML, Liu CJ, Lin CL, Huang YW, Hsu CS, Liu CH, Kuo SF, Pan CJ, Yang SS, Su CW, Chen PJ, Chen DS, Kao JH.

Antivir Ther. 2011;16(5):629-37. doi: 10.3851/IMP1841.

PMID:
21817184
10.

Polymorphisms near IL28B and serologic response to peginterferon in HBeAg-positive patients with chronic hepatitis B.

Sonneveld MJ, Wong VW, Woltman AM, Wong GL, Cakaloglu Y, Zeuzem S, Buster EH, Uitterlinden AG, Hansen BE, Chan HL, Janssen HL.

Gastroenterology. 2012 Mar;142(3):513-520.e1. doi: 10.1053/j.gastro.2011.11.025. Epub 2011 Nov 19.

PMID:
22108195
11.

Pegylated-interferon alpha therapy for treatment-experienced chronic hepatitis B patients.

Yeh ML, Peng CY, Dai CY, Lai HC, Huang CF, Hsieh MY, Huang JF, Chen SC, Lin ZY, Yu ML, Chuang WL.

PLoS One. 2015 Apr 2;10(4):e0122259. doi: 10.1371/journal.pone.0122259. eCollection 2015.

12.

[Twenty-four weeks therapy with peginterferon alfa-2a could be similar to 48 weeks therapy in patients with HBeAg positive chronic hepatitis B and good predictors of response: results of a pilot study].

Solari J, Galdame O, Rezzonico L, Frider B, Villamil A, Casciato P, Reig M, Bandi JC, Alessio A, Gadano A.

Acta Gastroenterol Latinoam. 2009 Dec;39(4):254-60. Spanish.

PMID:
20178254
13.

Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial).

Ning Q, Han M, Sun Y, Jiang J, Tan D, Hou J, Tang H, Sheng J, Zhao M.

J Hepatol. 2014 Oct;61(4):777-84. doi: 10.1016/j.jhep.2014.05.044. Epub 2014 Jun 7.

PMID:
24915612
14.

Improved efficacy by individualized combination therapy with Peg IFN-a 2a and ADV in HBeAg positive chronic hepatitis B patients.

Wang YD, Zhao CY, Wang W, Shen C, Lu HZ, Zhang L, Yu WY, Zhou JY, Yan WZ.

Hepatogastroenterology. 2012 May;59(115):680-6. doi: 10.5754/hge12183.

PMID:
22441104
15.

Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B.

Bonino F, Marcellin P, Lau GK, Hadziyannis S, Jin R, Piratvisuth T, Germanidis G, Yurdaydin C, Diago M, Gurel S, Lai MY, Brunetto MR, Farci P, Popescu M, McCloud P; Peginterferon Alfa-2a HBeAg-Negative Chronic Hepatitis B Study Group.

Gut. 2007 May;56(5):699-705. Epub 2006 Nov 24.

16.

[Efficacy of pegylated-interferon alpha-2a treatment in patients with HBeAg-positive chronic hepatitis B and partial viral response to nucleoside analogue therapy].

Li MH, Hu LP, Zhang L, Lu Y, Shen G, Wu SL, Chang M, Mu CQ, Wu YZ, Yang M, Song SJ, Zhang SF, Hua WH, Xie Y, Cheng J, Xu DZ.

Zhonghua Gan Zang Bing Za Zhi. 2015 Nov;23(11):826-31. doi: 10.3760/cma.j.issn.1007-3418.2015.11.006. Chinese.

PMID:
26743242
17.

Hepatitis B virus genotype B results in better immediate, late and sustained responses to peginterferon-alfa in hepatitis-B-e-antigen-positive patients.

Chen CH, Lee CM, Hung CH, Wang JH, Hu TH, Changchien CS, Lu SN.

J Gastroenterol Hepatol. 2011 Mar;26(3):461-8. doi: 10.1111/j.1440-1746.2010.06429.x.

PMID:
21332543
18.

Intrahepatic response markers in chronic hepatitis B patients treated with peginterferon alpha-2a and adefovir.

Takkenberg B, Terpstra V, Zaaijer H, Weegink C, Dijkgraaf M, Jansen P, Beld M, Reesink H.

J Gastroenterol Hepatol. 2011 Oct;26(10):1527-35. doi: 10.1111/j.1440-1746.2011.06766.x.

PMID:
21557773
19.

Safety and efficacy of two-step peginterferon α-2a treatment in patients of chronic hepatitis B with acute exacerbation.

Chen CC, Wang PC, Chang HW, Chen CF.

J Viral Hepat. 2012 Mar;19(3):161-72. doi: 10.1111/j.1365-2893.2011.01469.x. Epub 2011 Jul 4.

20.

Higher efficacy of sequential therapy with interferon-alpha and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients.

Sarin SK, Kumar M, Kumar R, Kazim SN, Guptan RC, Sakhuja P, Sharma BC.

Am J Gastroenterol. 2005 Nov;100(11):2463-71.

PMID:
16279901

Supplemental Content

Support Center